GPER1 has recently been postulated as a novel therapeutic target for treating obesity and comorbid metabolic dysfunctions on the basis of murine models showing that the selective GPER1 agonist G1 limited weight gain, reduced insulin resistance, and improved glucose and lipid homeostasis [129]. The gene discussed is GPER1; the disease is obesity due to melanocortin 4 receptor deficiency.